Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Lenaerts AJ, Bitting C, Woolhiser L, Gruppo V, Marietta KS, Johnson CM, Orme IM.

Antimicrob Agents Chemother. 2008 Apr;52(4):1513-5. doi: 10.1128/AAC.00897-07. Epub 2008 Feb 11.

2.

In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.

Lu J, Yue J, Wu J, Luo R, Hu Z, Li J, Bai Y, Tang Z, Xian Q, Zhang X, Wang H.

Pharmacology. 2010;85(6):365-71. doi: 10.1159/000299795. Epub 2010 Jun 8.

PMID:
20530976
3.

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM.

Antimicrob Agents Chemother. 2005 Jun;49(6):2294-301.

4.

In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.

Rao SS, Raghunathan R, Ekambaram R, Raghunathan M.

Int J Antimicrob Agents. 2009 Nov;34(5):451-3. doi: 10.1016/j.ijantimicag.2009.06.014. Epub 2009 Jul 22.

PMID:
19625168
5.

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

JI B, Lounis N, Truffot-Pernot C, Grosset J.

Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4.

6.

Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.

Ng PS, Manjunatha UH, Rao SP, Camacho LR, Ma NL, Herve M, Noble CG, Goh A, Peukert S, Diagana TT, Smith PW, Kondreddi RR.

Eur J Med Chem. 2015 Dec 1;106:144-56. doi: 10.1016/j.ejmech.2015.10.008. Epub 2015 Oct 14.

PMID:
26544629
7.

[Evaluation of new antitubercular agents--new quinolone agents].

Kawahara S, Eirei J.

Kekkaku. 1992 Oct;67(10):679-82. Japanese. No abstract available.

PMID:
1333544
8.

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J.

Antimicrob Agents Chemother. 2005 Jun;49(6):2289-93.

9.

In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains.

Oleksijew A, Meulbroek J, Ewing P, Jarvis K, Mitten M, Paige L, Tovcimak A, Nukkula M, Chu D, Alder JD.

Antimicrob Agents Chemother. 1998 Oct;42(10):2674-7.

10.

Prospects for new antitubercular drugs.

Duncan K, Barry CE 3rd.

Curr Opin Microbiol. 2004 Oct;7(5):460-5. Review.

PMID:
15451500
11.

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H.

Antimicrob Agents Chemother. 2004 Mar;48(3):780-2.

12.

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.

Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W.

Antimicrob Agents Chemother. 1993 Feb;37(2):183-6.

13.

In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.

Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1119-25. doi: 10.5588/ijtld.11.0752. Epub 2012 Jun 12.

PMID:
22691726
14.

Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.

Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu Y, Yamamura N, Hoshi M, Hirota T.

J Antimicrob Chemother. 2004 Oct;54(4):755-60. Epub 2004 Sep 3.

PMID:
15347635
15.

Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.

Hearn MJ, Cynamon MH.

J Antimicrob Chemother. 2004 Feb;53(2):185-91. Epub 2003 Dec 19.

PMID:
14688045
16.

[Determination of Mycobacterium tuberculosis' sensitivity to pyrazinamide on a BACTEC-960 bacteriological analyzer].

Irtuganova OA, Smirnova NS, Slogotskaia LV.

Probl Tuberk Bolezn Legk. 2003;(7):40-2. Russian. No abstract available.

PMID:
12939878
17.

Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.

Bogatcheva E, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Barbosa F, Einck L, Nacy CA, Protopopova M.

J Med Chem. 2006 Jun 1;49(11):3045-8.

19.

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

Alvirez-Freites EJ, Carter JL, Cynamon MH.

Antimicrob Agents Chemother. 2002 Apr;46(4):1022-5.

20.

Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.

Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD.

J Antimicrob Chemother. 2005 Dec;56(6):1169-71. Epub 2005 Oct 13.

PMID:
16223939

Supplemental Content

Support Center